Mepolizumab for CRSwNP (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
Han JK, Bachert C, Fokkens W, et al.
Lancet Respir Med · 2021
Grade ARCTn=407
Key Findings
- ●Significant NPS reduction at 52 weeks
- ●Reduced need for surgery
- ●Improved nasal obstruction VAS
- ●FDA-approved 2021 for CRSwNP
Referenced in (1 disease)
ID: pmid-33872587DOI: 10.1016/S2213-2600(21)00097-7PMID: 33872587